Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-31

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This was a randomized, double-blind, placebo-controlled parallel study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

NCT05702788

COVID-19 Pneumonia

WITHDRAWN PHASE2

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

NCT05686629

Novel COVID-19-Infected Pneumonia

UNKNOWN PHASE2

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

NCT05688839

Novel COVID-19-Infected Pneumonia

UNKNOWN PHASE2

Efficacy and Safety of SR1375 in Adult Patients With CAP

NCT06577558

Community-acquired Pneumonia

RECRUITING PHASE2

Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

NCT04469114

Covid19

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Jaktinib

Jaktinib 100mg BID

Group Type EXPERIMENTAL

Jaktinib

Intervention Type DRUG

100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.

Placebo

placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo (given as two placebo tablets) administered orally BID with best available treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Jaktinib

100mg of Jaktinib (given as two 50mg tablets) administered orally Twice daily(BID) with best available treatment.

Intervention Type DRUG

Placebo

Placebo (given as two placebo tablets) administered orally BID with best available treatment.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years of age, male or female;
* History of COVID-19 infection within 1 week;
* Subjects with HRCT consistent with viral pneumonia (Judged by investigator) and meeting any of the following criteria: With fever, respiratory symptoms; Shortness of breath present,RR ≥30 breaths/min.
* Clear consciousness, Capable and voluntary informed consent.

Exclusion Criteria

* Unable to take tablets orally Or suspected hypersensitivity to Jaktinib, drugs of the same class, or their excipients, Patients with severe gastrointestinal dysfunction affecting drug absorption;
* Any person meeting criteria for critical pneumonia;
* Patients considered unsuitable for this trial by the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No